Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk 42% in Phase 3

Adding the individualized neoantigen therapy intismeran autogene to adjuvant pembrolizumab reduced the risk of recurrence or death by 42% in resected high-risk melanoma, according to phase 3 INTerpath-001 data presented at the 2026 ESMO Congress in Madrid (NCT05933577). At a median follow-up of 24.6 months, the hazard ratio for recurrence-free survival was 0.58 (95% CI, 0.45–0.75; P < .001).

The trial enrolled 757 patients in the combination arm and 380 in the placebo plus pembrolizumab arm, all with resected stage IIB to IV melanoma (AJCC staging of disease extent after surgical removal). Twenty-four-month recurrence-free survival (RFS, the time without local or distant relapse) reached 82.2% (95% CI, 79.3%–84.8%) with the combination versus 70.0% (95% CI, 65.0%–74.5%) with pembrolizumab alone.

Distant metastasis-free survival also favored the combination, with a hazard ratio of 0.62 (95% CI, 0.45–0.85; P = .002) and 24-month rates of 88.5% versus 80.2%. The benefit is not yet matched by an overall survival signal. Overall survival data remained immature (HR, 0.77; 95% CI, 0.45–1.31; P = .33), a gap that will require longer follow-up to close.

Safety showed a modest increment. Grade 3 or higher adverse effects occurred in 23.6% of patients on the combination versus 20.3% on pembrolizumab alone — roughly a three-point difference, not the price of a markedly more toxic regimen. Whether that trade-off holds across broader real-world populations remains untested.

What did the experts make of INTerpath-001?

Georgina Long, MD, presented the study at the ESMO plenary session (abstract LBA1, October 23–27, 2026). OncLive gathered reactions from three investigators who follow cutaneous melanoma and broader immunotherapy research.

Mark Shackleton, MBBS, PhD, FRACP, director of oncology at Alfred Health and professor of oncology at Monash University in Melbourne, placed the result in historical context. "Thirty-, 40-plus years ago, people were removing melanomas and mushing them up and extracting proteins and then reinjecting them into patients to try and induce immune responses," he said. "This is the real modern, cutting-edge technology now that's being applied to see if that concept works."

Shackleton called the trial an important proof of concept. He said it "gives us tremendous impetus to go down that highly personalized, neoantigen-based approach" to improving immunotherapy effectiveness.

Dirk Schadendorf, MD, director and chair of the Department of Dermatology at University Hospital Essen and managing director of the West German Cancer Center, was more expansive about the platform. "We were all excited about seeing that a patient-specific neoantigen vaccine added to pembrolizumab made such a big difference in RFS and DMFS benefit," he said. "I believe that these mRNA vaccines will be a new step in oncology treatment over the next decade." That decade-long forecast is a prediction, not data; the current evidence covers two years of follow-up.

Daniel Heng, MD, MPH, FRCPC, clinical professor of medicine at the University of Calgary and head of medical oncology at the Arthur J.E. Child Comprehensive Cancer Centre, flagged the immediate translational question. "The most exciting was Georgina Long, MD's, presentation at the ESMO plenary, the INTerpath-001 study, looking at the Moderna vaccine plus pembrolizumab," he said. "That's in melanoma: can we translate that to renal cell carcinoma?"

Where does an adjuvant vaccine fit in the neoadjuvant era?

INTerpath-001 tested intismeran autogene after surgery, yet neoadjuvant immunotherapy (treatment given before resection) has progressively reshaped how resectable high-risk melanoma is managed. That tension defines the next research question.

Shackleton framed it directly: "It's pretty clear from the data published so far in previous studies that neoadjuvant immunotherapy for [patients with melanoma] is clearly better than no neoadjuvant therapy and adjuvant therapy only. Where this adjuvant approach of adding in personalized vaccination will fit in the neoadjuvant paradigm is the next interesting question."

He did not answer that question, and no trial reported at the congress did. The 42% reduction in recurrence risk establishes the concept; sequencing it against established neoadjuvant regimens, confirming an overall survival benefit, and extending the platform to other malignancies as Heng proposed are the open tasks for the trials that follow.